JP2023540679A5 - - Google Patents

Info

Publication number
JP2023540679A5
JP2023540679A5 JP2023505864A JP2023505864A JP2023540679A5 JP 2023540679 A5 JP2023540679 A5 JP 2023540679A5 JP 2023505864 A JP2023505864 A JP 2023505864A JP 2023505864 A JP2023505864 A JP 2023505864A JP 2023540679 A5 JP2023540679 A5 JP 2023540679A5
Authority
JP
Japan
Prior art keywords
lys
pro
isoglu
diacid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043581 external-priority patent/WO2022026631A1/en
Publication of JP2023540679A publication Critical patent/JP2023540679A/ja
Publication of JP2023540679A5 publication Critical patent/JP2023540679A5/ja
Priority to JP2025253353A priority Critical patent/JP2026048851A/ja
Pending legal-status Critical Current

Links

JP2023505864A 2020-07-28 2021-07-28 コンジュゲートされたヘプシジン模倣物 Pending JP2023540679A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025253353A JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063057574P 2020-07-28 2020-07-28
US202063057583P 2020-07-28 2020-07-28
US202063057577P 2020-07-28 2020-07-28
US202063057582P 2020-07-28 2020-07-28
US63/057,574 2020-07-28
US63/057,583 2020-07-28
US63/057,577 2020-07-28
US63/057,582 2020-07-28
US202163169527P 2021-04-01 2021-04-01
US202163169515P 2021-04-01 2021-04-01
US202163169533P 2021-04-01 2021-04-01
US63/169,515 2021-04-01
US63/169,533 2021-04-01
US63/169,527 2021-04-01
PCT/US2021/043581 WO2022026631A1 (en) 2020-07-28 2021-07-28 Conjugated hepcidin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025253353A Division JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Publications (2)

Publication Number Publication Date
JP2023540679A JP2023540679A (ja) 2023-09-26
JP2023540679A5 true JP2023540679A5 (cg-RX-API-DMAC7.html) 2024-08-06

Family

ID=80036079

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023505923A Active JP7871246B2 (ja) 2020-07-28 2021-07-28 コンジュゲート型ヘプシジン模倣体
JP2023505864A Pending JP2023540679A (ja) 2020-07-28 2021-07-28 コンジュゲートされたヘプシジン模倣物
JP2025186320A Pending JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体
JP2025253353A Pending JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023505923A Active JP7871246B2 (ja) 2020-07-28 2021-07-28 コンジュゲート型ヘプシジン模倣体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025186320A Pending JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体
JP2025253353A Pending JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Country Status (10)

Country Link
US (3) US20240018189A1 (cg-RX-API-DMAC7.html)
EP (2) EP4188413A4 (cg-RX-API-DMAC7.html)
JP (4) JP7871246B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053615A (cg-RX-API-DMAC7.html)
AU (2) AU2021316000A1 (cg-RX-API-DMAC7.html)
CA (2) CA3189432A1 (cg-RX-API-DMAC7.html)
IL (1) IL299530A (cg-RX-API-DMAC7.html)
MX (1) MX2023001292A (cg-RX-API-DMAC7.html)
PH (1) PH12023500004A1 (cg-RX-API-DMAC7.html)
WO (3) WO2022026631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2022212696A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2022212698A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20250170216A1 (en) * 2022-02-02 2025-05-29 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
BR112014013697A2 (pt) * 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR20170002414A (ko) * 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Similar Documents

Publication Publication Date Title
JP2023536463A5 (cg-RX-API-DMAC7.html)
US12269856B2 (en) Hepcidin analogues and uses thereof
JP2024513392A5 (cg-RX-API-DMAC7.html)
ES3058577T3 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
JP2024513391A5 (cg-RX-API-DMAC7.html)
JP2023540679A (ja) コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) Conjugated hepcidin mimetics
WO2022212696A1 (en) Conjugated hepcidin mimetics
JP2012530145A5 (cg-RX-API-DMAC7.html)
CA3214153A1 (en) Conjugated hepcidin mimetics
EA053112B1 (ru) Конъюгированные миметики гепсидина
AR125266A1 (es) Miméticos de hepcidina conjugados
CN116457000A (zh) 缀合的铁调素模拟物
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
HK1220112B (en) Hepcidin analogues and uses therof